US 12,351,592 B2
Metformin complexes with transition metals and P group elements
Richard Fernando Dvries Arturo, Cali (CO); Octavio Piñeros, Cali (CO); and Stephanny Villamizar Delgado, Cali (CO)
Assigned to UNIVERSIDAD SANTIAGO DE CALI, Cali (CO)
Appl. No. 17/610,031
Filed by UNIVERSIDAD SANTIAGO DE CALI, Cali (CO)
PCT Filed Aug. 7, 2020, PCT No. PCT/IB2020/057476
§ 371(c)(1), (2) Date Nov. 9, 2021,
PCT Pub. No. WO2021/024231, PCT Pub. Date Feb. 11, 2021.
Claims priority of provisional application 62/884,597, filed on Aug. 8, 2019.
Prior Publication US 2022/0315608 A1, Oct. 6, 2022
Int. Cl. C07F 1/08 (2006.01); C07F 3/06 (2006.01); C07F 9/94 (2006.01); C07F 15/02 (2006.01); C07F 15/04 (2006.01); C07F 15/06 (2006.01)
CPC C07F 1/08 (2013.01) [C07F 3/06 (2013.01); C07F 9/94 (2013.01); C07F 15/02 (2013.01); C07F 15/04 (2013.01); C07F 15/06 (2013.01); C07B 2200/13 (2013.01)] 4 Claims
 
1. A metformin-copper complex, wherein the metformin-copper complex is in a crystalline form characterized by a powder X-ray diffraction pattern comprising the following 2⊖ values: 9.65; 11.78; 14.05; 15.31; 16.42; 18.79; 18.90; 19.37; 20.31; 21.40; 23.15; 23.49; 23.82; 24.33; 24.80; 24.92; 25.25; 26.03; 26.82; 28.22; 29.07; 29.22; 30.33; 30.68; 31.48; 31.81; 32.00; 32.08; 33.02; 33.19; 33.61; 33.94; 34.59; 35.73; 36.04; 36.42; 36.72; 36.89; 37.07; 37.95; 38.21; 38.33; 38.58; 38.91; 39.19; 39.39; 40.54; 40.64; 40.80; 40.95; 41.30; 41.57; 41.79; 42.39; 42.86; 43.05; 43.23; 43.41; 43.59; 44.10; 44.23; 44.78; 45.10; 45.27; 45.86; 46.07; 46.94; 47.14; 47.33; 47.54; 48.02; 48.20; 48.45; 48.63; 48.84; 49.12; 49.52; and 49.72.